OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List

 
• By Sten Stovall
  
Laboratory
OSE and BI To Start OSE-172 Phase I Trials In Early 2019 • Source: Shutterstock

More from Strategy

More from Business